skip to main content
Idioma:

Effect of asthma and asthma medication on the prognosis of patients with COVID-19

Choi, Yong Jun ; Park, Ju-Young ; Lee, Hye Sun ; Suh, Jin ; Song, Jeung Yoon ; Byun, Min Kwang ; Cho, Jae Hwa ; Kim, Hyung Jung ; Lee, Jae-Hyun ; Park, Jung-Won ; Park, Hye Jung

The European respiratory journal, 2020, Vol.57 (3), p.2002226 [Periódico revisado por pares]

England: European Respiratory Society

Texto completo disponível

Citações Citado por
  • Título:
    Effect of asthma and asthma medication on the prognosis of patients with COVID-19
  • Autor: Choi, Yong Jun ; Park, Ju-Young ; Lee, Hye Sun ; Suh, Jin ; Song, Jeung Yoon ; Byun, Min Kwang ; Cho, Jae Hwa ; Kim, Hyung Jung ; Lee, Jae-Hyun ; Park, Jung-Won ; Park, Hye Jung
  • Assuntos: Adolescent ; Adult ; Aged ; Anti-Asthmatic Agents - therapeutic use ; Asthma - complications ; Asthma - drug therapy ; Child ; COVID-19 - complications ; COVID-19 - mortality ; Female ; Humans ; Male ; Middle Aged ; Original ; Prognosis ; Retrospective Studies ; Young Adult
  • É parte de: The European respiratory journal, 2020, Vol.57 (3), p.2002226
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Coronavirus disease 2019 (COVID-19) has spread worldwide rapidly. However, the effects of asthma, asthma medication and asthma severity on the clinical outcomes of COVID-19 have not yet been established. The study included 7590 de-identified patients, who were confirmed to have COVID-19 using the severe acute respiratory syndrome coronavirus 2 RNA-PCR tests conducted up to May 15, 2020; we used the linked-medical claims data provided by the Health Insurance Review and Assessment Service. Asthma and asthma severity (steps suggested by the Global Initiative for Asthma) were defined using the diagnostic code and history of asthma medication usage. Among 7590 COVID-19 patients, 218 (2.9%) had underlying asthma. The total medical cost associated with COVID-19 patients with underlying asthma was significantly higher than that of other patients. Mortality rate for COVID-19 patients with underlying asthma (7.8%) was significantly higher than that of other patients (2.8%; p<0.001). However, asthma was not an independent risk factor for the clinical outcomes of COVID-19 after adjustment, nor did asthma medication use and asthma severity affect the clinical outcomes of COVID-19. However, use of oral short-acting β -agonists was an independent factor to increase the total medical cost burden. Patients with step 5 asthma showed significant prolonged duration of admission compared to those with step 1 asthma in both univariate and multivariate analysis. Asthma led to poor outcomes of COVID-19; however, underlying asthma, use of asthma medication and asthma severity were not independent factors for poor clinical outcomes of COVID-19, generally.
  • Editor: England: European Respiratory Society
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.